Product Information
GUAIFENESIN-PSE ER 1200-120 MG is a generic product labeled by Dr. Reddy's Laboratories Inc., priced at $0.4235 per EA under NDC 55111079924. Its NADAC has been published 172 times since Dec 21, 2022.
FDA first approved this application on Dec 29, 2017.
Strength
1200; 120 mg/1; mg/1
Manufacturer
Dr. Reddy's Laboratories Inc.NDC
55111079924
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA208369FDA Approved
12/29/2017
On Market Since
12/29/2017
Pharmacological Classes
Price Statistics
The NADAC for GUAIFENESIN-PSE ER 1200-120 MG has been published 172 times since Dec 21, 2022, and over the history we have for it it has declined 24.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.4235 per EA |
|---|---|
| All-time high | $0.7195 (Feb 15, 2023) |
| All-time low | $0.4177 (Feb 18, 2026) |
| 52-week high | $0.4235 |
| 52-week low | $0.4177 |
| Median price | $0.5958 |
| Average price | $0.5696 |
| Largest weekly change | -29.9% (Feb 18, 2026) |
| Weeks tracked | 172 |
| Tracking since | Dec 21, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Guaifenesin and Pseudoephedrine HCL market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Dr. Reddy's Laboratories Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Guaifenesin and Pseudoephedrine HCL market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Expectorant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GUAIFENESIN-PSE ER 1200-120 MG?
The current National Average Drug Acquisition Cost (NADAC) for GUAIFENESIN-PSE ER 1200-120 MG, manufactured by Dr. Reddy's Laboratories Inc., is $0.4235 per EA (NDC 55111079924), effective Sep 30, 2026.
How has the price of GUAIFENESIN-PSE ER 1200-120 MG changed over time?
Over the history we have for it, the NADAC for GUAIFENESIN-PSE ER 1200-120 MG has declined 24.4%. It has been tracked across 172 weekly CMS publications since Dec 21, 2022.
What are the highest and lowest recorded NADAC prices for GUAIFENESIN-PSE ER 1200-120 MG?
Since Dec 21, 2022, the NADAC for GUAIFENESIN-PSE ER 1200-120 MG has ranged from a low of $0.4177 (Feb 18, 2026) to a high of $0.7195 (Feb 15, 2023), with a median of $0.5958 per EA.
Are there cheaper alternatives to GUAIFENESIN-PSE ER 1200-120 MG?
No other NADAC-published product currently shares the active ingredient and strength of GUAIFENESIN-PSE ER 1200-120 MG in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures GUAIFENESIN-PSE ER 1200-120 MG?
GUAIFENESIN-PSE ER 1200-120 MG (NDC 55111079924) is labeled by Dr. Reddy's Laboratories Inc., and CMS classifies it as a generic product.